Log in

NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

$97.92
+4.03 (+4.29 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$92.97
Now: $97.92
$99.69
50-Day Range
$75.43
MA: $84.54
$97.94
52-Week Range
$72.97
Now: $97.92
$109.42
Volume215,217 shs
Average Volume68,123 shs
Market Capitalization$3.77 billion
P/E Ratio13.54
Dividend YieldN/A
Beta0.52
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-4847-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$669.89 million
Cash Flow$7.89 per share
Book Value$49.59 per share

Profitability

Net Income$281.78 million

Miscellaneous

Employees1,464
Market Cap$3.77 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.


Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Monday, November, 4th. The company reported $1.46 EPS for the quarter, missing analysts' consensus estimates of $1.72 by $0.26. The firm earned $160.85 million during the quarter, compared to the consensus estimate of $168.60 million. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 brokers have issued 1 year price objectives for Taro Pharmaceutical Industries' shares. Their forecasts range from $110.00 to $110.00. On average, they expect Taro Pharmaceutical Industries' share price to reach $110.00 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
  • 1. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (11/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

Media headlines about TARO stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Taro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decrease in short interest in November. As of November 15th, there was short interest totalling 273,200 shares, a decrease of 11.5% from the October 31st total of 308,700 shares. Based on an average trading volume of 50,400 shares, the days-to-cover ratio is currently 5.4 days. Currently, 3.0% of the shares of the company are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional investors include CLARET ASSET MANAGEMENT Corp (0.22%), Millennium Management LLC (0.21%), California Public Employees Retirement System (0.11%), Systematic Financial Management LP (0.02%) and Squarepoint Ops LLC (0.01%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CLARET ASSET MANAGEMENT Corp and Systematic Financial Management LP.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Squarepoint Ops LLC.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $97.92.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $3.77 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel